[3M01-04] Medical RI production 1

[3M02] R&D on Medical RI production using domestic nuclear infrastructures to achieve self-preparedness (2)

(2)⁹⁹Mo and ²²⁵Ac pharmaceuticals market environment analysis

*Takeo Morooka¹, Yumi Kawata¹, Naoyuki Takaki² (1. Japan Medical Isotope, 2. TCU)

Keywords:Medical isotope, Domestically-produced 99Mo, Domestically-produced 225Ac

In switching the fission method produced ⁹⁹Mo to the activation method produced ⁹⁹Mo for use as a pharmaceutical raw material, pharmaceutical companies would be required to re-register their production methods as required by the pharmaceutical regulatory procedures, including updating their production lines for ⁹⁹Mo with relatively low specific activity. In assessing the commercial viability, it would be important to taking into account price competitiveness and supply stability in comparison with imported ⁹⁹Mo. The demand for ²²⁵Ac for medical use is currently limited to R&D purposes. In advancing commercial-scale domestic production of ²²⁵Ac, securing supply of ²²⁶Ra, the raw material for ²²⁵Ac, is essential, where the Government’s guidance and support is anticipated.